

DonorPlex® Pooled Donor Suspension Hepatocytes

With 10-, 20-, and 50-donor single and mixed gender pools of hepatocytes and a proprietary prediction algorithm, DonorPlex® Hepatocytes go beyond your expectations for a robust and consistent pooled donor hepatocyte product.

Maureen Bunger, Katherine Dunnick;
Lonza Walkersville, Inc., Walkersville, MD, USA

Introduction

Understanding hepatic drug metabolism using primary hepatocytes is important in order to meet stricter regulatory and safety testing requirements for market approval. To fully understand a population-based response for metabolism, researchers must use numerous different hepatocyte donors to get an average response. To address this need, cryopreserved hepatocytes that represent a pool of multiple individual donors are commonly used.




Figure 1. Robustness of pooling process. Three batches of 20 donors with identical donor composition were pooled on three separate dates. Activity values are shown representing our capability to reproduce pooled lots.

Catalog no.	Product description
HUCS10P, HUCS10F, HUCS10M	10 donor mixed gender or single gender
HUCS20P, HUCS20F, HUCS20M	20 donor mixed gender or single gender
HUCS50P	50 donor mixed gender

Table 1. Portfolio of our current DonorPlex® Hepatocyte Products.

We are now producing high quality cryopreserved pooled donor suspension hepatocyte lots. To further improve the utility of pooled donor hepatocytes, we also developed a proprietary algorithm to predict activity phenotype defined by customer specifications. Using our large inventory of single donor human hepatocyte lots and this unique algorithm, we can produce a variety of lots to fit customer's needs (Table 1).

Robust manufacturing

We optimized a robust manufacturing process to produce pooled donor lots with little variability. In Figure 1, we show the ability to reproducibly create a lot with the same phenotype on multiple different dates. The optimized manufacturing process also ensures each lot of pooled suspension hepatocytes meet stringent yield and viability specifications.

Prediction algorithm

Large batches of hepatocytes from pooling donors together can supply research programs for many years. When a new batch is needed, many researchers would like the new batch to be similar to the previous one. We use a proprietary algorithm to predict final activity of a pooled donor batch prior to manufacture. Shown in Figure 2 are the results of the predicted activity of a 20-donor pool compared to the actual activity. This gives us the unique ability to work with customers to create lots with specific CYP activity, or produce lots with CYP levels that represent the average population.




Figure 2. Prediction algorithm. Predicted activities versus measured activities for eight CYP enzymes, general ECOD metabolism and ECOD phase II enzymes (UGT and SULT) when individual donors are pooled together.

Transporter verification

Since pooling requires multiple freeze and thaw steps, transporters which reside on the cell surface can be damaged. To check whether the pooling method preserved transporter activity, we tested pools for OAT1B1/3, OCT1/2, and NTCIP active uptake. Results demonstrated that our pools have active transporters with fold change activity greater than 2-fold when compared to passive uptake (data not shown).

Characteristic	Substrate	Marker metabolite (pmol/million cells/min) (reported value)
CYP1A2	100 µM Phenacetin	Acetaminophen
CYP2A6	5 µM Coumarin	7-Hydroxycoumarin
CYP2B6	100 µM Bupropion	Hydroxybupropion
CYP2C9	50 µM Diclofenac	4-Hydroxydiclofenac
CYP2C19	30 µM Mephenytoin	4-Hydroxymephenytoin
CYP2D6	10 µM Dextromethorphan	Dextrorphan
CYP2E1	200 µM Chlorzoxazone	Hydroxychlorzoxazone
CYP3A4	100 µM Testosterone	6β-Hydroxytestosterone
CYP3A4	10 µM Midazolam	Hydroxymidazolam
General metabolism	100 µM 7-Ethoxycoumarin	7-Hydroxycoumarin
SULT	5 µM 7-Hydroxycoumarin	7-Hydroxycoumarin Sulfate
UGT	200 µM Hydroxycoumarin	7-Hydroxycoumarin Glucuronide

Table 2. Pooled donor suspension CYP specifications.

Summary

With our optimized pooling procedure, we can provide you with a variety of DonorPlex® Hepatocyte Configurations and sizes for your metabolism testing needs. Moreover, our predictive algorithm, helps to create customizable lots to meet specific CYP activity requirements.

Pooled donor suspension specifications:

Yield ≥ 5×10⁶ viable cells/vial

Customizable CYP, ECOD, and phase II ECOD metabolism activity, as measured by LCMS metabolite formation using model chemicals (Table 2).

OAT1B1/1B3, OCT1, and NCTP transporter activity ratio in a facilitated active uptake study using model chemicals.

Contact us

North America

Customer Service: +1 800 638 8174 (toll free)
 order.us@lonza.com
 Scientific Support: +1 800 521 0390 (toll free)
 scientific.support@lonza.com

Europe

Customer Service: +32 87 321 611
 order.europe@lonza.com
 Scientific Support: +49 221 99199 400
 scientific.support.eu@lonza.com

International

Contact your local Lonza distributor
 Customer Service: +1 301 898 7025
 scientific.support@lonza.com

Lonza Walkersville, Inc. – Walkersville, MD 21793

Learn more.



For research use only. Not for use in diagnostic procedures.

All trademarks belong to Lonza, registered in USA, EU or CH or to third party owners and used only for informational purposes. The information contained herein is believed to be correct and corresponds to the latest state of scientific and technical knowledge. However, no warranty is made, either expressed or implied, regarding its accuracy or the results to be obtained from the use of such information and no warranty is expressed or implied concerning the use of these products. The buyer assumes all risks of use and/or handling. Any user must make his own determination and satisfy himself that the products supplied by Lonza Group Ltd or its affiliates and the information and recommendations given by Lonza Group Ltd or its affiliates are (i) suitable for intended process or purpose, (ii) in compliance with environmental, health and safety regulations, and (iii) will not infringe any third party's intellectual property rights. The user bears the sole responsibility for determining the existence of any such third party rights, as well as obtaining any necessary licenses. For more details: www.lonza.com/legal.

©2025 Lonza. All rights reserved.

CS-DS031 06/25

bioscience.lonza.com
www.lonza.com/pdh